The bill strengthens device safety and FDA oversight by requiring advance notices, rapid reporting, and validated reprocessing tests—improving patient protection and clinician information—but it raises regulatory compliance burdens, legal risks, and short-term availability/cost concerns for manufacturers, hospitals, and patients.
Patients who use reusable or implanted medical devices and the hospitals that treat them: will likely face fewer device-related safety incidents because manufacturers must give advance notice of design or reprocessing changes and reprocessing tests must meet FDA validation standards.
FDA and regulators: gain earlier visibility into device design/reprocessing changes and foreign communications, enabling faster investigations and corrective actions when safety issues arise.
Hospitals, clinics, and clinicians: receive clearer, earlier information about device changes and validated reprocessing procedures, helping them assess compatibility with clinical protocols and reduce patient risk from unexpected modifications.
Manufacturers (including small firms) and hospitals: will face increased compliance and administrative costs to provide pre-change notices, foreign-communication reports, and validated reprocessing data, which could raise device and service prices for healthcare providers and patients.
Manufacturers and patients/hospitals: treating failure to notify as 'adulteration' and enforcing 5‑day reporting deadlines creates legal and market risks (seizures, enforcement) that could deter smaller entrants and risk supply disruptions of devices.
Patients and clinicians: the advance-notice and short reporting processes could slow manufacturers' ability to push urgent safety fixes or iterative improvements if the notification process is time-consuming, delaying beneficial updates.
Based on analysis of 4 sections of legislative text.
Requires manufacturers to notify FDA before design/reprocessing changes, report certain foreign communications within 5 days, and requires validated instructions/validation data for listed rapid reprocessing tests.
Introduced March 26, 2025 by Ted Lieu · Last progress March 26, 2025
Requires medical device makers to notify the FDA before changing device designs or instructions for how to clean/reprocess devices and to report certain communications to foreign health providers about design or safety changes within five days. Adds "rapid assessment tests" used to check proper reprocessing of reusable devices to the FDA’s device rules and requires those tests to include validated instructions and validation data in premarket 510(k) notices; the FDA must publish and maintain a list of such test types and can refuse 510(k) submissions that lack the required validation information.